Personalis Q2 FY26 net loss widens to $31.68 million; revenue rises 30% to $22.36 million
PSNL•Q2 FY26 results and business updates
- Personalis posted Q2 revenue growth of 30% to USD 22.4 million, while net loss widened to USD 31.68 million, or USD 0.30 a share.
- Clinical diagnostic revenue more than doubled to USD 2.6 million, while clinical test volume rose 199% year over year to 10,384 tests.
- Pharma testing services revenue climbed 51% to USD 16.79 million, while population sequencing revenue slipped 9% to USD 3 million.
- Medicare coverage expanded NeXT Personal reimbursement to four indications, adding approvals for immunotherapy monitoring and neoadjuvant breast cancer monitoring.
- Chris Hall said more than 1,400 physicians ordered NeXT Personal; Personalis withdrew guidance following its Tempus merger agreement.
